拜耳,强生的Xarelto未能达到PhIII的目标

2018-08-28 MedSci MedSci原创

在静脉血栓栓塞和心力衰竭研究的两项研究中,拜耳和强生公司扩大血液稀释剂Xarelto应用范围的计划遭遇挫折。MARINER试验显示,Xarelto(利伐沙班)并未降低出院后急性医疗患者静脉血栓栓塞(VTE)或血栓和VTE相关死亡的复合终点。然而,该公司指出,该药物确实显着降低了VTE的安全性,增强了药物的正面利益风险。Janssen 研究与发展部心血管与代谢全球治疗领域负责人James List说



在静脉血栓栓塞和心力衰竭研究的两项研究中,拜耳和强生公司扩大血液稀释剂Xarelto应用范围的计划遭遇挫折。

MARINER试验显示,Xarelto(利伐沙班)并未降低出院后急性医疗患者静脉血栓栓塞(VTE)或血栓和VTE相关死亡的复合终点。

然而,该公司指出,该药物确实显着降低了VTE的安全性,增强了药物的正面利益风险。

Janssen 研究与发展部血管与代谢全球治疗领域负责人James List说,除了已经批准的三种Xarelto VTE适应症之外,结果"讲述了它在预防VTE治疗适当的急性医疗病人(包括住院和出院后)静脉血栓栓赛方面的作用。

"综合这些发现,我们看到了批准申请的希望,并期待与美国食品和药物管理局讨论。"

在COMMANDER HF评估结果中,与标准治疗相比,药物对有症状性心衰至少三个月的急性失代偿性心力衰竭(ADHF)发作后降低心脏病发作,中风和死亡风险的影响,Xarelto没有影响总体死亡率。

然而,在患有严重冠状动脉疾病且左心室射血分数降低且最近出现ADHF发作的患者中,该药物的心脏病发作和中风数量较少。

"这些结果表明,这些患者的高死亡率主要是由心脏功能不良引起的,而不是血栓。"研究小组强调说。

"自从推出以来,Xarelto已被批准用于各种适应症并在全球范围内开出超过4200万次。基于这一坚实的基础,COMMANDER HF and MARINER试验的这些发现将帮助科学界更好地理解血栓在许多不同疾病状态的发病率和死亡率中的潜在作用。


此文系梅斯医学(MedSci)原创整理编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1972833, encodeId=a42b19e283366, content=<a href='/topic/show?id=f9f2141900c' target=_blank style='color:#2F92EE;'>#PhIII的目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14190, encryptionId=f9f2141900c, topicName=PhIII的目标)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Mon Jul 22 05:41:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916036, encodeId=27aa19160364b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 24 09:41:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271682, encodeId=425912e168276, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318476, encodeId=d92c13184e6cd, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590838, encodeId=652315908381a, content=<a href='/topic/show?id=13e518e9564' target=_blank style='color:#2F92EE;'>#Xarelto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18795, encryptionId=13e518e9564, topicName=Xarelto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=175417868335, createdName=wushaoling, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341742, encodeId=287c341e4205, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:31 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341681, encodeId=d43a3416817e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:12:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341516, encodeId=8d8a341516b7, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:04:48 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341507, encodeId=351134150ed9, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:01:56 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1972833, encodeId=a42b19e283366, content=<a href='/topic/show?id=f9f2141900c' target=_blank style='color:#2F92EE;'>#PhIII的目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14190, encryptionId=f9f2141900c, topicName=PhIII的目标)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Mon Jul 22 05:41:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916036, encodeId=27aa19160364b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 24 09:41:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271682, encodeId=425912e168276, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318476, encodeId=d92c13184e6cd, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590838, encodeId=652315908381a, content=<a href='/topic/show?id=13e518e9564' target=_blank style='color:#2F92EE;'>#Xarelto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18795, encryptionId=13e518e9564, topicName=Xarelto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=175417868335, createdName=wushaoling, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341742, encodeId=287c341e4205, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:31 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341681, encodeId=d43a3416817e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:12:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341516, encodeId=8d8a341516b7, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:04:48 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341507, encodeId=351134150ed9, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:01:56 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2019-01-24 juliusluan78
  3. [GetPortalCommentsPageByObjectIdResponse(id=1972833, encodeId=a42b19e283366, content=<a href='/topic/show?id=f9f2141900c' target=_blank style='color:#2F92EE;'>#PhIII的目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14190, encryptionId=f9f2141900c, topicName=PhIII的目标)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Mon Jul 22 05:41:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916036, encodeId=27aa19160364b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 24 09:41:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271682, encodeId=425912e168276, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318476, encodeId=d92c13184e6cd, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590838, encodeId=652315908381a, content=<a href='/topic/show?id=13e518e9564' target=_blank style='color:#2F92EE;'>#Xarelto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18795, encryptionId=13e518e9564, topicName=Xarelto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=175417868335, createdName=wushaoling, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341742, encodeId=287c341e4205, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:31 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341681, encodeId=d43a3416817e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:12:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341516, encodeId=8d8a341516b7, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:04:48 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341507, encodeId=351134150ed9, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:01:56 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1972833, encodeId=a42b19e283366, content=<a href='/topic/show?id=f9f2141900c' target=_blank style='color:#2F92EE;'>#PhIII的目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14190, encryptionId=f9f2141900c, topicName=PhIII的目标)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Mon Jul 22 05:41:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916036, encodeId=27aa19160364b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 24 09:41:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271682, encodeId=425912e168276, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318476, encodeId=d92c13184e6cd, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590838, encodeId=652315908381a, content=<a href='/topic/show?id=13e518e9564' target=_blank style='color:#2F92EE;'>#Xarelto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18795, encryptionId=13e518e9564, topicName=Xarelto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=175417868335, createdName=wushaoling, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341742, encodeId=287c341e4205, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:31 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341681, encodeId=d43a3416817e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:12:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341516, encodeId=8d8a341516b7, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:04:48 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341507, encodeId=351134150ed9, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:01:56 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-30 ying_wu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1972833, encodeId=a42b19e283366, content=<a href='/topic/show?id=f9f2141900c' target=_blank style='color:#2F92EE;'>#PhIII的目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14190, encryptionId=f9f2141900c, topicName=PhIII的目标)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Mon Jul 22 05:41:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916036, encodeId=27aa19160364b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 24 09:41:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271682, encodeId=425912e168276, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318476, encodeId=d92c13184e6cd, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590838, encodeId=652315908381a, content=<a href='/topic/show?id=13e518e9564' target=_blank style='color:#2F92EE;'>#Xarelto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18795, encryptionId=13e518e9564, topicName=Xarelto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=175417868335, createdName=wushaoling, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341742, encodeId=287c341e4205, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:31 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341681, encodeId=d43a3416817e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:12:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341516, encodeId=8d8a341516b7, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:04:48 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341507, encodeId=351134150ed9, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:01:56 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1972833, encodeId=a42b19e283366, content=<a href='/topic/show?id=f9f2141900c' target=_blank style='color:#2F92EE;'>#PhIII的目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14190, encryptionId=f9f2141900c, topicName=PhIII的目标)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Mon Jul 22 05:41:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916036, encodeId=27aa19160364b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 24 09:41:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271682, encodeId=425912e168276, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318476, encodeId=d92c13184e6cd, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590838, encodeId=652315908381a, content=<a href='/topic/show?id=13e518e9564' target=_blank style='color:#2F92EE;'>#Xarelto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18795, encryptionId=13e518e9564, topicName=Xarelto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=175417868335, createdName=wushaoling, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341742, encodeId=287c341e4205, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:31 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341681, encodeId=d43a3416817e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:12:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341516, encodeId=8d8a341516b7, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:04:48 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341507, encodeId=351134150ed9, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:01:56 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-30 liumin1987

    谢谢分享,学习了。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1972833, encodeId=a42b19e283366, content=<a href='/topic/show?id=f9f2141900c' target=_blank style='color:#2F92EE;'>#PhIII的目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14190, encryptionId=f9f2141900c, topicName=PhIII的目标)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Mon Jul 22 05:41:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916036, encodeId=27aa19160364b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 24 09:41:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271682, encodeId=425912e168276, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318476, encodeId=d92c13184e6cd, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590838, encodeId=652315908381a, content=<a href='/topic/show?id=13e518e9564' target=_blank style='color:#2F92EE;'>#Xarelto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18795, encryptionId=13e518e9564, topicName=Xarelto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=175417868335, createdName=wushaoling, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341742, encodeId=287c341e4205, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:31 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341681, encodeId=d43a3416817e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:12:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341516, encodeId=8d8a341516b7, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:04:48 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341507, encodeId=351134150ed9, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:01:56 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-30 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1972833, encodeId=a42b19e283366, content=<a href='/topic/show?id=f9f2141900c' target=_blank style='color:#2F92EE;'>#PhIII的目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14190, encryptionId=f9f2141900c, topicName=PhIII的目标)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Mon Jul 22 05:41:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916036, encodeId=27aa19160364b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 24 09:41:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271682, encodeId=425912e168276, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318476, encodeId=d92c13184e6cd, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590838, encodeId=652315908381a, content=<a href='/topic/show?id=13e518e9564' target=_blank style='color:#2F92EE;'>#Xarelto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18795, encryptionId=13e518e9564, topicName=Xarelto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=175417868335, createdName=wushaoling, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341742, encodeId=287c341e4205, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:31 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341681, encodeId=d43a3416817e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:12:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341516, encodeId=8d8a341516b7, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:04:48 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341507, encodeId=351134150ed9, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:01:56 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-28 天地飞扬

    了解一下,谢谢分享!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1972833, encodeId=a42b19e283366, content=<a href='/topic/show?id=f9f2141900c' target=_blank style='color:#2F92EE;'>#PhIII的目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14190, encryptionId=f9f2141900c, topicName=PhIII的目标)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Mon Jul 22 05:41:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916036, encodeId=27aa19160364b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 24 09:41:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271682, encodeId=425912e168276, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318476, encodeId=d92c13184e6cd, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590838, encodeId=652315908381a, content=<a href='/topic/show?id=13e518e9564' target=_blank style='color:#2F92EE;'>#Xarelto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18795, encryptionId=13e518e9564, topicName=Xarelto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=175417868335, createdName=wushaoling, createdTime=Thu Aug 30 11:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341742, encodeId=287c341e4205, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:31 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341681, encodeId=d43a3416817e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:12:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341516, encodeId=8d8a341516b7, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:04:48 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341507, encodeId=351134150ed9, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:01:56 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-28 惠映实验室

    学习了,谢谢分享。

    0

相关资讯

拜耳赢得欧盟监管机构对更广泛的Xarelto使用的认可

拜耳近日宣布欧洲药品管理局的人用药品委员会(CHMP)采取积极意见,将Xarelto扩大到动脉粥样硬化患者的治疗。该公司表示,如果更广泛的使用获得批准,大约3000万名患者可能从口服Xarelto(Xa抑制剂)中获益。